Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends Tysabri for multiple sclerosis

Elan and Biogen have received a recommendation for its multiple sclerosis drug Tysabri from NICE

Irish pharmaceutical company Elan and US partner Biogen have received a recommendation for its multiple sclerosis drug Tysabri (natalizumab) from the UK's National Institute of Clinical Excellence (NICE).

NICE, which assesses the cost-effectiveness of drugs and other medical treatments, recommended Tysabri for the treatment of a severe form of MS known as highly active relapsing remitting MS.

Elan shares were up EUR 0.53 to reach EUR 16.66 in Dublin in pm trading on 3 July.

Tysabri will be competing with Teva's established MS therapy, Copaxone (glatiramer acetate). In FY06, in-market global sales of Copaxone reached USD 1.4bn, an increase of 20 per cent on FY05 figures. Sales of Copaxone in the EU increased 26 per cent to reach USD 498m, driven by significant sales increases in the UK, France and Germany, which are the largest MS markets in Europe.

Teva still has not developed an effective oral version of Copaxone, but is in clinical trials with the oral MS drug, laquinimod, in partnership with Sweden-based Lundbeck.

Tysabri, which was developed by Biogen and Elan, was launched in November 2004. However, in February 2005, it was banned not only for use, but also from clinical trials after being implicated in the development of a fatal cerebral viral infection, known as progressive multifocal leukoencephalopathy (PML). Two MS patients taking Tysabri also died after developing progressive multi-focal leucoencephalopathy, a neurodegenerative disease.

Despite the study results, Tysabri fought off the negative press, based on its efficacy and ease of use. Copaxone and other MS treatments are usually administered by injection on a daily basis, while Tysabri is given as a monthly infusion. In June 2006, US regulators reinstated Tysabri's marketing license, with certain caveats imposed.

Tysabri has new labelling warning that it increases the risk of developing PML, which is described as an opportunistic viral infection of the brain that usually leads to death or severe disability.

The new labelling also notes that the known cases of PML were limited to patients with recent or concomitant exposure to immunomodulators or immunosuppressants, which left them more vulnerable to infections. There were not enough cases, however, to rule out the possibility that PML may occur with Tysabri monotherapy.

4th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics